Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy

Purpose: Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume (SV) and its changes affect progression-free (PFS) and overall surviva...

Descripció completa

Dades bibliogràfiques

Autors principals:	Christina Quell, Wolfgang G. Kunz, Viktoria Blumenberg, Kai Rejeski, Veit L. Bücklein, Maria Ingenerf, Christian Schmidt, Gabriel T. Sheikh, Matthias Brendel, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Michael Winkelmann
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-01-01
Col·lecció:	Cancer Treatment and Research Communications
Matèries:	Spleen CAR T-cell therapy Non-Hodgkin-Lymphoma Immunotherapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2468294225002163
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!